CD19/BCMA HLA-independent TCR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus - Trial NCT06349343
Access comprehensive clinical trial information for NCT06349343 through Pure Global AI's free database. This Phase 1 trial is sponsored by Wuhan Union Hospital, China and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Wuhan Union Hospital, China
Timeline & Enrollment
Phase 1
Apr 01, 2024
Jan 01, 2026
Primary Outcome
Safety and tolerability
Summary
The purpose of the study is to explore the safety and efficacy of cluster of differentiation
 19 (CD19)/B cell maturation antigen (BCMA) human leukocyte antigen (HLA)-independent T cell
 receptor (TCR) -T therapy in refractory/moderate-to-severe systemic lupus erythematosus(SLE).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06349343
Non-Device Trial